Cargando…
Novel L-nucleoside analog, 5-fluorotroxacitabine, displays potent efficacy against acute myeloid leukemia
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849559/ https://www.ncbi.nlm.nih.gov/pubmed/31857370 http://dx.doi.org/10.3324/haematol.2019.226795 |
_version_ | 1783645329428578304 |
---|---|
author | Bankar, Aniket Siriwardena, Thirushi Piyumika Rizoska, Biljana Rydergård, Christina Kylefjord, Helen Rraklli, Vilma Eneroth, Anders Pinho, Pedro Norin, Stefan Bylund, Johan Moses, Sara Bethell, Richard Kavanagh, Simon Maclean, Neil Gronda, Marcela Wang, Xiaoming Hurren, Rose Minden, Mark D. Targett-Adams, Paul Schimmer, Aaron D. Albertella, Mark |
author_facet | Bankar, Aniket Siriwardena, Thirushi Piyumika Rizoska, Biljana Rydergård, Christina Kylefjord, Helen Rraklli, Vilma Eneroth, Anders Pinho, Pedro Norin, Stefan Bylund, Johan Moses, Sara Bethell, Richard Kavanagh, Simon Maclean, Neil Gronda, Marcela Wang, Xiaoming Hurren, Rose Minden, Mark D. Targett-Adams, Paul Schimmer, Aaron D. Albertella, Mark |
author_sort | Bankar, Aniket |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-7849559 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Fondazione Ferrata Storti |
record_format | MEDLINE/PubMed |
spelling | pubmed-78495592021-02-03 Novel L-nucleoside analog, 5-fluorotroxacitabine, displays potent efficacy against acute myeloid leukemia Bankar, Aniket Siriwardena, Thirushi Piyumika Rizoska, Biljana Rydergård, Christina Kylefjord, Helen Rraklli, Vilma Eneroth, Anders Pinho, Pedro Norin, Stefan Bylund, Johan Moses, Sara Bethell, Richard Kavanagh, Simon Maclean, Neil Gronda, Marcela Wang, Xiaoming Hurren, Rose Minden, Mark D. Targett-Adams, Paul Schimmer, Aaron D. Albertella, Mark Haematologica Letters to the Editor Fondazione Ferrata Storti 2019-12-19 /pmc/articles/PMC7849559/ /pubmed/31857370 http://dx.doi.org/10.3324/haematol.2019.226795 Text en Copyright© 2021 Ferrata Storti Foundation http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
spellingShingle | Letters to the Editor Bankar, Aniket Siriwardena, Thirushi Piyumika Rizoska, Biljana Rydergård, Christina Kylefjord, Helen Rraklli, Vilma Eneroth, Anders Pinho, Pedro Norin, Stefan Bylund, Johan Moses, Sara Bethell, Richard Kavanagh, Simon Maclean, Neil Gronda, Marcela Wang, Xiaoming Hurren, Rose Minden, Mark D. Targett-Adams, Paul Schimmer, Aaron D. Albertella, Mark Novel L-nucleoside analog, 5-fluorotroxacitabine, displays potent efficacy against acute myeloid leukemia |
title | Novel L-nucleoside analog, 5-fluorotroxacitabine, displays potent efficacy against acute myeloid leukemia |
title_full | Novel L-nucleoside analog, 5-fluorotroxacitabine, displays potent efficacy against acute myeloid leukemia |
title_fullStr | Novel L-nucleoside analog, 5-fluorotroxacitabine, displays potent efficacy against acute myeloid leukemia |
title_full_unstemmed | Novel L-nucleoside analog, 5-fluorotroxacitabine, displays potent efficacy against acute myeloid leukemia |
title_short | Novel L-nucleoside analog, 5-fluorotroxacitabine, displays potent efficacy against acute myeloid leukemia |
title_sort | novel l-nucleoside analog, 5-fluorotroxacitabine, displays potent efficacy against acute myeloid leukemia |
topic | Letters to the Editor |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849559/ https://www.ncbi.nlm.nih.gov/pubmed/31857370 http://dx.doi.org/10.3324/haematol.2019.226795 |
work_keys_str_mv | AT bankaraniket novellnucleosideanalog5fluorotroxacitabinedisplayspotentefficacyagainstacutemyeloidleukemia AT siriwardenathirushipiyumika novellnucleosideanalog5fluorotroxacitabinedisplayspotentefficacyagainstacutemyeloidleukemia AT rizoskabiljana novellnucleosideanalog5fluorotroxacitabinedisplayspotentefficacyagainstacutemyeloidleukemia AT rydergardchristina novellnucleosideanalog5fluorotroxacitabinedisplayspotentefficacyagainstacutemyeloidleukemia AT kylefjordhelen novellnucleosideanalog5fluorotroxacitabinedisplayspotentefficacyagainstacutemyeloidleukemia AT rrakllivilma novellnucleosideanalog5fluorotroxacitabinedisplayspotentefficacyagainstacutemyeloidleukemia AT enerothanders novellnucleosideanalog5fluorotroxacitabinedisplayspotentefficacyagainstacutemyeloidleukemia AT pinhopedro novellnucleosideanalog5fluorotroxacitabinedisplayspotentefficacyagainstacutemyeloidleukemia AT norinstefan novellnucleosideanalog5fluorotroxacitabinedisplayspotentefficacyagainstacutemyeloidleukemia AT bylundjohan novellnucleosideanalog5fluorotroxacitabinedisplayspotentefficacyagainstacutemyeloidleukemia AT mosessara novellnucleosideanalog5fluorotroxacitabinedisplayspotentefficacyagainstacutemyeloidleukemia AT bethellrichard novellnucleosideanalog5fluorotroxacitabinedisplayspotentefficacyagainstacutemyeloidleukemia AT kavanaghsimon novellnucleosideanalog5fluorotroxacitabinedisplayspotentefficacyagainstacutemyeloidleukemia AT macleanneil novellnucleosideanalog5fluorotroxacitabinedisplayspotentefficacyagainstacutemyeloidleukemia AT grondamarcela novellnucleosideanalog5fluorotroxacitabinedisplayspotentefficacyagainstacutemyeloidleukemia AT wangxiaoming novellnucleosideanalog5fluorotroxacitabinedisplayspotentefficacyagainstacutemyeloidleukemia AT hurrenrose novellnucleosideanalog5fluorotroxacitabinedisplayspotentefficacyagainstacutemyeloidleukemia AT mindenmarkd novellnucleosideanalog5fluorotroxacitabinedisplayspotentefficacyagainstacutemyeloidleukemia AT targettadamspaul novellnucleosideanalog5fluorotroxacitabinedisplayspotentefficacyagainstacutemyeloidleukemia AT schimmeraarond novellnucleosideanalog5fluorotroxacitabinedisplayspotentefficacyagainstacutemyeloidleukemia AT albertellamark novellnucleosideanalog5fluorotroxacitabinedisplayspotentefficacyagainstacutemyeloidleukemia |